Alnylam Pharmaceuticals (@Alnylam) header
Alnylam Pharmaceuticals (@Alnylam) profile picture

Leader in #RNAiTherapeutics. Pioneer of this innovative approach to silencing the genes that cause disease. Community guidelines: https://teapawt.net/t.co/AgfAVlmSG2.

Cambridge, MA
Joined August 2009
Photo by Alnylam Pharmaceuticals (@Alnylam)Photo by Alnylam Pharmaceuticals (@Alnylam)Photo by Alnylam Pharmaceuticals (@Alnylam)Photo by Alnylam Pharmaceuticals (@Alnylam)Photo by Alnylam Pharmaceuticals (@Alnylam)Photo by Alnylam Pharmaceuticals (@Alnylam)Photo by Alnylam Pharmaceuticals (@Alnylam)Photo by Alnylam Pharmaceuticals (@Alnylam)Photo by Alnylam Pharmaceuticals (@Alnylam)Photo by Alnylam Pharmaceuticals (@Alnylam)
Rock, paper, scissors is a game of chance but recurring kidney stones shouldn’t be. Across Alnylam, we’re marking #HyperoxaluriaAwarenessWeek by shining a light on Primary Hyperoxaluria Type 1 (PH1). 💡 Kidney stones in kids or recurring in adults? Ask your healthcare team about PH1. #PH1 #Hyperoxaluria
2
4
443
This #VeteransDay, we honor all those who have served, including the veterans within our Alnylam community. We’re grateful for your service, dedication and the contributions you continue to make each day. Thank you for all that you do. #AlnylamProud
1
1
7
407
Alnylam collaborator Regeneron presented promising first-in-human results for an investigational RNAi therapeutic (also known as an siRNA therapeutic) in patients with metabolic dysfunction-associated steatotic liver disease (#MASLD) during an oral session at #AASLD2026 that were also published by NEJM.  go-alnylam.com/4zbGHHE #siRNA #RNAi #RNAiTherapeutics
2
3
1
32
2,085
Early recognition of transthyretin #amyloidosis with cardiomyopathy (#ATTR-CM) impacts lives, yet it remains underdiagnosed. We’re proud to support @American_Heart’s IMPACT ATTR initiative to help clinicians diagnose earlier and improve the quality and consistency of care.

1
2
11
607
Every patient story matters. At @American_Heart (AHA) in Chicago, visit Alnylam booth 2818 to watch former professional football player Pete’s journey with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and why greater disease awareness matters.
1
3
7
634
Discover the new transthyretin #amyloidosis with cardiomyopathy (#ATTR-CM) data we’ll be presenting at upcoming congresses. 📍 First stop is the @American_Heart (AHA) #ScientificSessions26 📍 Then we’ll be heading to the @ISA_Amyloidosis Symposium #ISA2026

1
7
598
This #HyperoxaluriaAwarenessWeek, we’re helping raise awareness for Primary Hyperoxaluria Type 1 (PH1). One kidney stone might seem like chance, but recurring stones in adults, or any stones in children, may point to symptoms that shouldn't be ignored. bit.ly/3UDiJRP #PH1 #Hyperoxaluria
5
549
As Health Literacy Month comes to a close, we’re breaking down the basics of clinical trials: what they are, why they matter and the important role they play in advancing new medicines. At Alnylam, helping people understand clinical research is one way we can better connect our science with the people we hope to serve. Watch the video to learn more. Read more about our trials: go-alnylam.com/4sGrTze
3
498
The future of cardiology needs more women at the forefront. Through our work with @WomenAs1, we’re helping expand opportunities for mentorship, collaboration and leadership development to support the next generation of women leaders.

1
3
3
599
We've reported Q3 2026 financial results and highlights of recent period activity. Join us LIVE TODAY at 8:30 AM ET to hear from our leadership or access the replay later today at: go-alnylam.com/4BDX1n8 Read the Q3 2026 financial results press release: go-alnylam.com/4yJSgFF
1
5
1,510
Last week employees at Alnylam showed up in a big way to support the communities where we live and work. Just how big was our annual Community Service Week this year? 🌍 13 Countries 🏢 30+ Organizations supported 💪 750+ Volunteers ⏰ 2,000+ Volunteer hours At Alnylam, making a positive impact goes beyond the innovative medicines we develop. It’s also about fostering a culture of service and giving back, driven by a shared passion for making a difference.
10
563
Join us for a live webcast this Thursday, October 29th at 8:30 AM ET when we'll share Third Quarter 2026 financial results. Register, and access the replay later that day: bit.ly/4BBJM6n #RNAi #RNAitherapeutics #siRNA

3
460
What if you don’t know the question to ask? Ozzie & Mike took different paths to an ATTR cardiac amyloidosis diagnosis. Now, they’re sharing the key things they’ve learned and the questions they wish they had known to ask sooner.

8
556
There remains an urgent need for scientific progress in #HuntingtonsDisease (HD). Hear from Toby Ferguson, our Head of Neuroscience, about our commitment to advancing research for people living with HD, and you can watch the replay of our latest #RNAi Roundtable here: go-alnylam.com/4z08RpP
1
1
7
670
This @AmyloidosisDay, we’re proud to support #BeTheLink, shining a light on caregivers’ vital role. Art’s wife, Liz encourages him to share what he’s really experiencing with his physician, being the “voice” that helps him advocate for himself.
1
11
529
For Investors and Media Join us today at 10:00 AM ET for the 10th #RNAi Roundtable webinar featuring a discussion of the latest data from our investigational program in #HuntingtonsDisease (HD). Click the link to join the live webinar or access the replay approximately three hours after the event: bit.ly/48k3oy8
1
7
669
For #WorldAmyloidosisDay, we’re honoring caregivers. Caregiving needs can evolve daily and span years, so it’s essential for caregivers to look after their own well-being. Hear Ester’s' perspective as a former carer & current ATTR amyloidosis patient: bit.ly/4ijDOOJ
1
5
516
For the eighth year in a row, Alnylam has been recognized as a Science Top Employer! It's a reflection of our incredible people, our culture and our commitment to bold science. As we continue to expand the possibilities of RNAi, one thing is clear: we're just getting started. go-alnylam.com/4eJcHva #ChallengeAccepted
4
466
We’re presenting new data on our investigational #RNAi therapeutic in #HuntingtonsDisease (HD) at the European Huntington’s Disease Network (EHDN) Clinical Research Congress. #EHDN2026 Read the full press release: go-alnylam.com/4eNHffj
1
3
1
31
5,836
For Investors and Media Join us on 10/26 at 10:00 AM ET for the 10th #RNAi Roundtable focused on our latest advances in #HuntingtonsDisease (HD). Hear from the Alnylam team and scientific experts as they discuss our Phase 1b data in HD. Register here:go-alnylam.com/4z08RpP
4
571